BioShanghai Week 2026
BioShanghai Week 2026 (or Shanghai International Biopharma Industry Week) will be held September 17–20, 2026 at Zhangjiang Science Hall, Shanghai. Since its sixth edition, BioShanghai Week has become a iconic platform for biopharmaceutical innovation and…
CBI 2026 – Antibody Drug Development Conference
Bispecific antibody deal volumes continue to hit record highs, as the battlefield for antibody therapeutics rapidly expands from oncology into multi-billion-dollar markets such as autoimmune diseases, chronic conditions, and cardiovascular disorders.…
CBI 2026 – XDC Drug Development Conference
Currently, antibody-drug conjugates (ADCs) have entered a critical phase characterized by intensive clinical advancement and commercialization. Meanwhile, emerging technological platforms such as peptide-drug conjugates (PDCs) and radionuclide-conjugated…
China Medicine Connect Expo 2026
China Medicine Connect Expo 2026 is a large pharmaceutical/biotech industry event covering innovative drugs, biologics, CGT, ADC/XDC, peptides, CMC, manufacturing and partnering. Organizers expect 800+ pharma companies and substantial…
China’s NMPA Conditionally Approves GenrixBio’s Velinotamig for Heavily Pretreated Multiple Myeloma
China’s National Medical Products Administration (NMPA) has granted conditional approval to velinotamig (GR1803), a BCMA×CD3 bispecific antibody developed by Genrix Bio and partnered with Fosun Pharma’s YaoPharma, for adults with heavily pretreated…
Haisco Strikes $1.5 Billion NewCo Deal with Sentivera for Type 2 Inflammation Asset
Chinese drugmaker Haisco Pharmaceutical Group has struck another billion-dollar cross-border transaction, licensing ex-Greater China rights to a preclinical immunology asset to newly formed U.S. biotech Sentivera in a deal potentially worth more than…
LaNova Medicines’ Next-Generation Nectin-4 ADC LM-364 Wins China IND Clearance for Advanced Solid Tumors
LaNova Medicines has received clearance from China’s National Medical Products Administration (NMPA) to advance LM-364, its next-generation tumor microenvironment-responsive Nectin-4 antibody-drug conjugate (ADC), into clinical development for patients…
Hengrui Advances SHR-8203 Into Phase 1/2 Study in Advanced Solid Tumors, With Filing Hinting at Potential PD-1/VEGF/CTLA-4 Trispecific
Chinese pharmaceutical giant Hengrui Pharma has registered a new clinical study of SHR-8203 injection on China’s drug trial registration platform, moving the previously undisclosed biologic into a multicenter Phase 1/2 trial in patients with…
HUTCHMED’s Savolitinib-Tagrisso Combo Delivers Positive Phase 3 Results in MET-Driven EGFR-Mutated NSCLC
HUTCHMED has announced positive topline results from the global Phase 3 SAFFRON trial, showing that the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) delivered statistically significant and clinically meaningful improvements in both…
Hopstem completes nearly 200 million yuan Series C financing to accelerate its core iPSC programs.
On August 10, 2026, Zhejiang Hopstem Biotechnology Co., Ltd. (or Hopstem) announced the completion of the first tranche of its nearly RMB 200 million Series C financing. This round of financing was jointly participated in by new shareholders Tasly…